Comparison of two management strategies for Helicobacter pylori treatment: Clinical study and cost-effectiveness analysis

Helicobacter

Volumn 10, Issue 1, 2005, Pages 22-32

  Marko, Dritana ^a   Calvet, Xavier ^b,g   Ducons, Julio ^c   Guardiola, Jordi ^d   Tito, Llucia ^e   Bory, Felipe ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

^d Department of Internal Medicine   (Spain)

^e HOSPITAL DE L ESPERIT SANT   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL DE SABADELL   (Spain)

Author keywords

Helicobacter pylori; Treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ANALYSIS; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG EFFICACY; ERADICATION THERAPY; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; MULTICENTER STUDY; PEPTIC ULCER; PRIORITY JOURNAL; PROBABILITY; QUADRUPLE THERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TRIPLE THERAPY; UREA BREATH TEST;

ADULT; AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; TETRACYCLINE; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 13944278454     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2005.00288.x     Document Type: Article

References (29)

1. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000;118:S2-8.
2. Gisbert JP, Calvet X, Gomollon F, et al. Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference. Med Clin (Barc) 2000;114:185-95.
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
4. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996;275:622-9.
5. Veldhuyzen VZ, Parley A, Marcon N, et al. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study. Can J Gastroenterol 2000;14:599-602.
6. Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Aliment Pharmacol Ther 2002;16:1261-7.
7. Gomollon F, Valdeperez J, Garuz R, et al. Cost-effectiveness analysis of two strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care. Med Clin (Barc) 2000;115:1-6.
8. Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication. The QUADRATE Study Gastroenterol 2002;123:1763-9.
9. Laine L, Hunt R, El Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7.
10. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14:1237-43.
11. Gene E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003;17:1137-43.
12. de Boer WA, Tytgat GN. Regular review. Treatment of Helicobacter pylori infection. BMJ 2000;320:31-4.
13. Gisbert JP, Pajares JM. Treatment of Helicobacter pylori eradication failures. Curr Treat Options Gastroenterol 2003;6:147-56.
14. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997;40:459-62.
15. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999;319:635-8.
16. Sanchez LA. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature. Am J Health Syst Pharm 1999;56:1630-8.
17. Calvet X, Gene E, Lopez T, et al. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther 2001;15:1067-76.
18. Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9:15-25.
19. Logan RP, Walker MM. ABC of the upper gastrointestinal tract. Epidemiology and diagnosis of Helicobacter pylori infection. BMJ 2001;323:920-2.
20. Kernick DP. Economic evaluation in health: a thumb nail sketch. BMJ 1998;316:1663-5.
21. Gene E, Calvet X, Azagra R. Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers - a cost-effectiveness analysis. Aliment Pharmacol Ther 2000;14:433-42.
22. Gisbert JP, Calvet X, Bujanda L, et al. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-4.
23. Diari Oficial de la Generalitat de Catalunya, no. 3736,Ordre SSS/337/2002. September 30. Cited 2003 April 5: Available from: URL: http:// www.gencat.es/diari/3736/02268027.htm.
24. Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects. Med Clin (Barc) 2000;114:46-53.
25. Vademécum Internacional. http://vademecum. medicom.es/paginas_htm/ FramesetPrincipal.asp. Cited February 2003.
26. Vakil N, Rhew D, Soll A, et al. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol 2000;95:1691-8.
27. Ofman J, Wallace J, Badamgarav E, et al. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage. Am J Gastroenterol 2002;97:1941-50.
28. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999;94:725-9.
29. New York State Registered Pharmacy. RxUSA. Available from: URL. http://www.rxusa.com. Cited February 2003.